Quick Answer
Caris Life Sciences, Inc. reported Stockholders Equity of $577.31 million for the year ending 2025.
- Caris Life Sciences, Inc. showed an increase of +123.1% in Stockholders Equity from 2024 to 2025.
- This data is from Caris Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$2.27 billion | Q2 2024: -$2.36 billion | Q3 2024: -$2.44 billion | Q1 2025: -$2.60 billion | Q2 2025: $452.90 million | Q3 2025: $478.36 million.
- Over the full 4 years of available data (2022 to 2025), Caris Life Sciences, Inc.'s Stockholders Equity has grown by 133.9%.
- Historical annual values: Fiscal year 2025: $577.31 million | Fiscal year 2024: -$2.50 billion | Fiscal year 2023: -$2.14 billion | Fiscal year 2022: -$1.70 billion.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: